A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies
Objective
Primary Objective: Ph I Component: To establish DLT & MTD, and RP2D of neratinib in r/r pediatric malignancies Ph II Component: To assess the efficacy of neratinib in r/r pediatric malignancies at the RP2D